Naratriptan Teva Uk (Naratriptan)

Naratriptan is a Triptan indicated for the acute management of migraine within the migraine disease pathway.

• Migraine without aura: provides rapid relief of headache intensity and associated symptoms.
• Migraine with aura: reduces the severity of headache following aura onset.
• Acute migraine attacks: enables patients to abort an attack when taken early.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of these receptors causes vasoconstriction of intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the migraine cascade and alleviating headache pain. The combined vascular and neuronal effects contribute to its efficacy in aborting migraine episodes.

Naratriptan may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Nausea: mild stomach upset or urge to vomit.
• Dry mouth: reduced salivation leading to a parched feeling.
• Tingling sensation: paresthesia in extremities.

Serious or Rare Side Effects

• Chest discomfort: pressure or pain that may mimic cardiac events.
• Severe hypertension: sudden increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Vasospasm: constriction of blood vessels causing ischemic symptoms.

When prescribing Naratriptan, clinicians should observe several precautionary measures to ensure patient safety.

• Cardiovascular disease: avoid use in patients with uncontrolled hypertension, coronary artery disease, or history of stroke.
• Concomitant serotonergic drugs: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors.
• Hepatic impairment: consider dose adjustment or alternative therapy in moderate to severe liver dysfunction.
• Age considerations: use with caution in elderly patients due to increased sensitivity to vascular effects.
• Pregnancy and lactation: evaluate risk–benefit ratio; limited data are available.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Naratriptan can interact with other medicines, and interactions are classified by their clinical significance.

Major Interactions (Avoid)

• Ergot alkaloids: concurrent use may cause additive vasoconstriction and severe hypertension.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may elevate serotonin levels.
• Antihypertensive agents: Naratriptan may reduce the effectiveness of blood pressure‑lowering drugs.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise plasma concentrations of Naratriptan.